Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (OVHIPEC-2)
Stephanie N. Gregory(National Institutes of Health), S. Lot Aronson(The Netherlands Cancer Institute), Jonathan M. Hernandez(National Institutes of Health), Willemien J. van Driel(The Netherlands Cancer Institute), Gabe S. Sonke(Oncode Institute), Oliver Zivanovic(Memorial Sloan Kettering Cancer Center), Carrie E. Ryan(University at Buffalo, State University of New York)
Cited by 3
Related Papers
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k
Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial
|Journal of Clinical Oncology|2015|655
Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs
|Cancer Treatment Reviews|2016|609
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
(untitled)
|Edinburgh Research Explorer|0|353